Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptotagmin-1 is a synaptic vesicle integral membrane protein serving as the principal calcium sensor for fast, synchronous neurotransmitter release in the central nervous system[1][3][6][8]. It contains an N-terminal transmembrane domain and two cytoplasmic C2 domains (C2A and C2B) that bind Ca\(^{2+}\) and acidic phospholipids[3][5]. Upon Ca\(^{2+}\) influx during an action potential, synaptotagmin-1 interacts with the SNARE complex and phospholipids, triggering rapid synaptic vesicle fusion and neurotransmitter release[1][5][6]. It also acts as a molecular clamp, suppressing spontaneous and asynchronous release through oligomerization and interactions with complexin and SNARE proteins[2][5]. Mutations in SYT1 can impair synaptic function and are associated with some neuropsychiatric disorders[8]. While it is not currently the direct target of any approved therapeutic, it represents a mechanistic node essential for synaptic communication.
Calcium-dependent activation of fast synaptic vesicle fusion by binding Ca\(^{2+}\) and acidic phospholipids, displacing complexin from the SNARE complex, and enabling SNARE-mediated membrane fusion[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptotagmin-1 (SYT1).